SCHEMBL20005832

SCHEMBL20005832

CC(C)(C)OC(=O)NC[C@@]1(c2cc(F)cc(F)c2)C[C@H]1CC(N)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
RORC P51449 1/20 0.35
HCRTR2 O43614 1/20 0.33
DPP8 Q6V1X1 2/20 0.33
DPP9 Q86TI2 2/20 0.33
GRM2 Q14416 1/20 0.33
NFKB1 P19838 1/20 0.32
NFKB2 Q00653 1/20 0.32
RELA Q04206 1/20 0.32
DRD2 P14416 3/20 0.31
PARP1 P09874 1/20 0.31
HSD11B1 P28845 2/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31
SERPINE1 P05121 1/20 0.30
KDM4A O75164 1/20 0.30
EPHX1 P07099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20005716 0.87 HCRTR2 (0.35) HCRTR2DPP8DPP9GRM2NFKB1
SCHEMBL20005977 0.87 HCRTR2 (0.35) HCRTR2DPP8DPP9GRM2NFKB1
SCHEMBL20005952 0.83 CTSS (0.37) HCRTR2
SCHEMBL21527861 0.82 HCRTR1 (0.31) HCRTR2HSD11B1
SCHEMBL20005951 0.77 ACACB (0.35) RORCCA12CA1CA2CA9
SCHEMBL13720547 0.71 IDO1 (0.41) DRD2CA12CA1KDM4A
SCHEMBL29891320 0.70 DPP8 (0.38) RORCHCRTR2DPP8DPP9GRM2
SCHEMBL21135750 0.70 DPP8 (0.38) RORCHCRTR2DPP8DPP9GRM2
SCHEMBL13698145 0.69 SLC6A3 (0.48) DRD2
SCHEMBL22917996 0.69 SLC6A3 (0.48) DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2022-01-20 US disclosed
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors BIAL—PORTELA & CA, S.A. (PT) 2021-04-13 US disclosed
WO-2018056854-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS BIAL - PORTELA & Cª, S.A. (PT) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017523-A1 BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS DBH, SLC6A3, SLC6A2 MAOA 15/4885MAOB 6/4885RORC 2110/4885
US-10975083-B2 Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors DBH, SLC6A3, SLC6A2 MAOA 14/4885MAOB 6/4885RORC 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.